ePT--the Electronic Newsletter of Pharmaceutical Technology, Jan 3, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jan 3, 2013
News
Mylan Recalls Painkiller Pills due to Risk of Higher Dosage
By Adeline Siew, PhD
Mylan issued a voluntary recall of three lots of the painkiller tablets hydrocodone bitartrate and acetaminophen.
GSK Partners with Vodafone for Vaccinations
By Stephanie Sutton
GlaxoSmithKline has formed a partnership with Vodafone to use mobile technology to help vaccinate more children against common infectious diseases in Africa.
FDA Approvals of NMEs and BLAs Increased in 2012
By Patricia Van Arnum
Additional approvals in December have helped to outpace a recent high set in 2011.
BASF Extends Offer Period to Acquire Pronova BioPharma
By Adeline Siew, PhD
BASF extended its offer period to acquire Pronova BioPharma, a producer of omega-3 fatty acids.
Week of December 31, 2012: Mylan, Orion Enter Into Comtan Settlement Agreement; Takeda, Amylin Terminate Agreement to Codevelop and Commercialize Compounds for Obesity; and More
Mylan, Orion Enter Into Comtan Settlement Agreement; Takeda, Amylin Termination Agreement to Codevelop and Commercialize Compounds for Obesity; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here